Investment firms Enavate Sciences, Jeito Capital, Blue Owl Healthcare Opportunities, Longitude Capital, OrbiMed, Logos Capital ... and founding investors Novo Holdings and Forbion taking part.

In a report released today, Justin Smith from Bernstein maintained a Buy rating on Roche Holding AG (RHHVF – Research Report), with a price ...

In a report released today, James Quigley from Goldman Sachs maintained a Sell rating on Roche Holding AG (RHHVF – Research Report), with a ...

Over the twelve months to December 2024, Roche Holding recorded an accrual ratio of -0.13. That implies it has good cash conversion, and implies that its free cash flow solidly exceeded its profit ...

Prior to this announcement, Roche Holding's dividend made up quite a large proportion of earnings but only 51% of free cash flows. This leaves plenty of cash for reinvestment into the business.

We recently published a list of 10 Best Annual Dividend Stocks To Buy Now. In this article, we are going to take a look at where Roche Holding AG (OTC:RHHBY) stands against other best annual dividend ...

Over the twelve months to December 2024, Roche Holding recorded an accrual ratio of -0.13. That implies it has good cash conversion, and implies that its free cash flow solidly exceeded its profit ...

In this article, we are going to take a look at where Roche Holding AG (OTC:RHHVF) stands against Morgan Stanley’s other European AI stocks. In August last year, investment bank Morgan Stanley ...

Earnings per share (EPS) missed analyst estimates by 38%. The primary driver behind last 12 months revenue was the Pharmaceuticals - Roche Pharmaceuticals segment contributing a total revenue of CHF46 ...

Roche Holding AG released its Q4 and full-year 2024 earnings yesterday. I'm broadly encouraged, although I wanted to hear more about the three GLP-1 agonist assets. Sales were up ~7%, and core EPS ...